WO1998003185A1 - Remedes contre l'hyperphosphatemie - Google Patents
Remedes contre l'hyperphosphatemie Download PDFInfo
- Publication number
- WO1998003185A1 WO1998003185A1 PCT/JP1997/002486 JP9702486W WO9803185A1 WO 1998003185 A1 WO1998003185 A1 WO 1998003185A1 JP 9702486 W JP9702486 W JP 9702486W WO 9803185 A1 WO9803185 A1 WO 9803185A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- resin
- ions
- weakly basic
- basic anion
- hyperphosphatemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
Definitions
- the present invention relates to a medicament containing a weakly basic anion exchange resin to which a ferric ion is chelated, as an active ingredient.
- the above medicament is useful as a therapeutic and / or prophylactic agent for hyperphosphatemia.
- hyperphosphatemia Patients with chronic renal failure usually have to undergo regular dialysis treatment for a long period of time, but often develop elevated levels of plasma phosphorus (> 4.5 mg / dl), so-called hyperphosphatemia .
- Oral administration of a therapeutic agent for the disease is common.
- aluminum hydroxide gel and precipitated calcium carbonate are used as therapeutic agents for hyperphosphatemia.
- phosphate ions in a living body are polymerized by a polymer such as polyallylamine and polyethyleneimine (preferably a polymer crosslinked by a crosslinking agent such as epichlorohydrin). Methods for removal are described.
- strong basic anion exchange resins represented by Dowex, require a large amount of dosage due to the low adsorption of phosphate ions, and have the potential to absorb bile salts. It is taught to be unfavorable, and it is explained that the above-mentioned polymer is improved in the above points as compared with the conventional resin.
- Aluminum hydroxide gel which is used as a therapeutic agent for hyperphosphatemia, has a problem in that it is administered at a high dose per day and has a bad taste, and it is difficult for patients to take the gel. Also, dissociated from aluminum hydroxide gel by gastric acid Aluminum ions are absorbed from the intestinal tract, and as a result of long-term administration, aluminum may deposit on the brain and bones, causing so-called aluminum osteopathy, aluminum encephalopathy, or microcytic anemia. On the other hand, precipitated calcium carbonate used as a therapeutic agent for hyperphosphatemia has the drawback that calcium ions generated by dissociation with stomach acid cause hypertensive lucidemia.
- WO94Z276221 describes a method of binding iron ions with a polymer containing an amino group, and it is intended to use a polystyrene-based or acryl-based resin having an amino group. If administered as is, the above side effects (iron deficiency anemia) may occur. Disclosure of the invention
- an object of the present invention is effective in treating and preventing or preventing hyperphosphatemia. It is to provide a medicine having no effect. More specifically, an object of the present invention is to provide a therapeutic and / or prophylactic agent for hyperphosphatemia having excellent phosphate removing ability and capable of selectively removing phosphate. Another object of the present invention is to provide a method for treating and preventing or preventing hyperphosphatemia.
- the present inventors have conducted various studies to achieve the above object, and as a result, it has been found that a weakly basic anion-exchange resin in which ferric ions are chemically bound to phosphate ions efficiently in vivo. What can be done, and if this resin is used as a medicine, They found no side effects such as bone disease, aluminum encephalopathy, hypercalcemia, and iron deficiency anemia.
- the present invention has been completed based on these findings. That is, the present invention provides a drug containing as an active ingredient a weakly basic anion-exchange resin to which a ferric ion is chelated, preferably the above drug used as a therapeutic and / or prophylactic agent for hyperphosphatemia. Things.
- the above-mentioned medicament comprising, as an active ingredient, a polyamine type weakly basic anion exchange resin in which ferric ions are chelated.
- the above-mentioned medicine containing, as an active ingredient, an acrylic weakly basic anion exchange resin to which ferric ions are chelated.
- medicaments preferably the therapeutic and / or prophylactic agents for hyperphosphatemia, are typically provided in the form of a pharmaceutical composition comprising the above active ingredient and a pharmaceutically acceptable excipient.
- a use of a weakly basic anion exchange resin to which a ferric ion is chelated comprising a medicament as defined above, preferably for the treatment of hyperphosphatemia and Z or Use is provided for the manufacture of a prophylactic agent.
- the weakly basic anion exchange resin is a polyamine-type or acryl-based resin.
- a method for treating hyperphosphatemia comprising a step of treating a weakly basic anion exchange resin to which ferric ions are chelated and administering a Z or prophylactically effective amount to a patient. And / or prophylactic methods are provided.
- the weakly basic anion exchange resin is a polyamine-type or acryl-based resin.
- Figure 1 shows the resin (WA10-Fe, WA20-Fe, WA21-Fe, IRA-67-Fe) in which ferric ion was chelated to the weakly basic anion exchange resin, and the p of precipitated calcium carbonate.
- 3 is a graph showing a change in the amount of phosphoric acid adsorbed by H. BEST MODE FOR CARRYING OUT THE INVENTION
- the present invention comprises, as an active ingredient, a weakly basic anion exchange resin in which ferric ion is chelated, preferably a polyamine type or acryl-based weakly basic anion exchange resin as an active ingredient, and comprises hyperphosphatemia.
- a weakly basic anion exchange resin in which ferric ion is chelated preferably a polyamine type or acryl-based weakly basic anion exchange resin as an active ingredient, and comprises hyperphosphatemia.
- the present invention relates to the invention of a medicament used as an agent for treating and / or preventing a disease.
- the weakly basic anion exchange resin used as a raw material for producing the medicament of the present invention is not particularly limited as long as it can adsorb phosphate ions.
- Preferred weakly basic anion exchange resins include polyamine type resin (polyamine) which is a reaction product of a styrene / divinylbenzene copolymer and a methylentriamine or a compound of a compound mainly containing arylamine, vinylamine and the like.
- Type resin or an acrylic resin which is a copolymer of amide compound such as acrylic acid or methacrylic acid and dimethylaminopropylamine and divinylbenzene.
- the above-mentioned weakly basic anion exchange resin in which a part thereof is substituted with a strongly basic exchange group such as trimethylamine or dimethylethanolamine may be used.
- known resins conventionally used for treating water, sugar solutions, and the like for example, Diaion WA10, WA20, WA21, WA30 (all manufactured by Mitsubishi Chemical Corporation), Amber Light IRA-35, IRA-67 (IRA-68), IRA-93ZU, IRA-94S, IRA-478 (all sold by Organo), WGR-2 (manufactured by Dow Chemical), etc. be able to.
- the weakly basic anion-exchange resin to which chelate-bonded ferric ions used as an active ingredient of the medicament of the present invention is, for example, described above, in an aqueous solution of a metal salt such as ferric chloride.
- a metal salt such as ferric chloride.
- the weakly basic anion exchange resin to which the ferric ion is chelated is described above.
- the resin (C1 form) obtained by the above method is treated with an alkaline solution such as sodium hydroxide solution to remove chloride ions, and then washed with water, whereby ferric ions and hydroxide ions are removed. It can be produced as a resin (OH form) which is bonded (adsorbed) or from which hydroxide ions are further released from this resin.
- a weakly basic anion-exchange resin in which ferric ions are chemically bound by the above method When a weakly basic anion-exchange resin in which ferric ions are chemically bound by the above method is produced, it varies depending on the type of the resin, but usually, 0.2 to 50 ing of iron is contained in the dried resin lg. A resin containing a certain amount is obtained. However, the amount of iron contained in the weakly basic anion exchange resin is not limited to this range, and the method for producing a weakly basic anion exchange resin in which ferric ions are chemically bonded is also described above. It is not limited to.
- the medicament of the present invention contains a weakly basic anion exchange resin in which ferric ion is chelated, preferably the above H-form resin as an active ingredient, and a combination of two or more of the above resins. May be included.
- the above-mentioned resin prepared in the form of a spherical product or a crushed product may be directly administered to patients, but generally, pharmaceutical additives generally used in the art are used. It is preferable to produce a pharmaceutical composition using one or more of the above and administer it to a patient.
- forms such as powders, granules, tablets, capsules and the like can be appropriately selected.
- compositions For example, after preparing a composition containing a resin (type C1) in which ferric ion is chelated, a pharmaceutical composition coated with an enteric coating such as hydroxypropylmethylcellulose phthalate dimethacrylate copolymer L is used. It is also possible to use compositions.
- Oral administration of a weakly basic ion-exchange resin results in the binding of chloride ions to nitrogen atoms in the resin (which are positively charged in gastric juice) or the formation of hydroxyl groups ionically bonded to the resin.
- a weakly basic ion-exchange resin in which ferric ions are chelate-bound can efficiently adsorb phosphate ions even through coordination bonds since the iron site has a ligand.
- useful metal ions iron ions, zinc ions, calcium ions, magnesium ions, etc.
- the medicament of the present invention is characterized in that it can selectively adsorb and remove only phosphoric acid without substantially adsorbing bile acids such as cholic acid, deoxycholic acid, and taurocholic acid.
- a weakly basic ion-exchange resin in which ferric ions are chelate-bonded may have a certain degree of release of ferric ions in artificial gastric fluid, but must not release ferric ions in artificial intestinal fluid at all. Has been confirmed. Therefore, even if the medicament of the present invention reaches the intestinal tract and comes into contact with intestinal fluid, there is no withdrawal of ferric ion and it is considered that there is almost no effect on the living body. Furthermore, since ferric ion is hardly absorbed in the living body and iron itself has substantially no toxicity, even if a small amount of ferric ion is detached from the pharmaceutical of the present invention, the adverse effect on the living body is not affected. It is thought that there is no. However, for patients in whom an increase in iron ions is not desirable, it is possible to completely suppress the release of ferric ions in the stomach by using a pharmaceutical composition in which an enteric coating is applied to a C1 type resin. I want it.
- the active ingredient of the medicament of the present invention is chemically very stable and is not absorbed at all from the gastrointestinal tract, the possibility of developing side effects such as toxicity due to the resin itself is extremely low.
- the type of hyperphosphatemia to which the medicament of the present invention is applied is not particularly limited. It can be administered to patients with renal dysfunction requiring therapy, such as chronic renal failure, for the treatment and prevention of hyperphosphatemia caused by dialysis therapy.
- the dose of the medicament of the present invention is not particularly limited, but generally, it is possible to administer 1 to 100 g, preferably about 5 to 30 g per day for an adult.
- Example 1 Production of resin in which ferric ion is chelated
- step (b) The resin obtained in the same manner as in the above step (a) (however, before drying under reduced pressure) is filled in a ram and passed over about 1 to 2 days with 70 tnL of a lmol / L sodium hydroxide solution. Liquid. Thereafter, the resin was thoroughly washed with purified water, and then dried at 40 to 80 ° C. under reduced pressure to obtain a resin (OH type) on which ferric ion was adsorbed.
- Coating liquid 30 g of hydroxymethyl pyrethroid cellulose lid L (HP50, manufactured by Shin-Etsu Chemical Co., Ltd.) was dispersed in 510 g of ethanol, and 60 g of purified water was added to dissolve it to produce a coating liquid.
- a resin in which ferric ion is chelated to lOOmL of a 0.02% sodium phosphate solution previously adjusted with sodium hydroxide solution or hydrochloric acid to adjust the pH to about 2 to 8 [Example One prepared by the method of step (a) 1: WA10-Fe, WA20-Fe, WA21-Fe, IRA-67-Fe], or 0.05 g of precipitated calcium carbonate (CaC0 :! ) was added. Each mixture was filtered after stirring for 1 hour at 37 ° C, Ion phosphate in the filtrate (PO 4 - 3) was measured by phosphorylation molybdenum blue method. The results are shown in Figure 1.
- the resins WA10-Fe, WA20-Fe, WA21_Fe, and IRA-67-Fe, in which ferric ions are chelated have a pH of 4 or more (neutral to weak). Phosphate ions were well adsorbed on the alkaline side. Therefore, all of these resins are expected to have a phosphate removing effect in the intestinal tract. In addition, these resins had a phosphate adsorption capacity equal to or higher than that of the precipitated calcium carbonate agent used as a first-line drug for hyperphosphatemia.
- Example 4 Desorption of iron ions from the medicament of the present invention
- the amount of ferric ion in the chelating-bonded basic anion-exchange resin is determined by the cross-linkage and shape (porous, hypo-, etc.) of resins having exchange groups of the same chemical structure. (Las, gel type), but slightly different due to pulverization, etc., but contained about 0.5 to 30 nig iron per lg in the dry state.
- Ferrous chloride (FeCl). A 0.2 mM solution of each of zinc chloride (ZnCl 2 ), magnesium chloride (MgCl 2 ), and chloride (CaCl 2 ). ), And the mixture is stirred for 1 hour at room temperature.
- Buffer A mixture of 10 mM imidazole and 5 ⁇ lactic acid, ⁇ 4.5 (adjusted with 1 ⁇ acetic acid)
- Injection method pressurization method 2.5 sec at 50 mbar
- Example 6 Adsorption of bile acids on the medicament of the present invention
- WA10-Fe and IRA-67-Fe produced by the method of step (a) and step (b) of Example 1 were used as test drugs, and cholestyramine was used as a control drug.
- a mixture containing an equal amount of a 2 mg / ml suspension of the sample and a 5 mM aqueous bile acid solution was stirred at 37 ° C for 1 hour, and the bile acid adsorbed on the sample was removed using a chromatodisk (0.45 / 1 m). The amount of bile acid adsorbed on the sample was determined from the amount of bile acid in the filtrate.
- Bile acids were quantified by enzymatic method using EnzaPile 2 (Daiichi Pure Chemicals Co., Ltd.). Table 3 shows the results. Table 3
- the amount of phosphorus (inorganic phosphorus) in urine was measured using an auto analyzer (COBAS PARA).
- the amount of phosphorus in the feces was determined by drying the feces, decomposing the organic matter by wet oxidation using a semi-microgel system, and measuring the ion phosphate by the phosphomolybdenum blue method.
- the results are shown in Table 4 (effect on urinary phosphorus excretion) and Table 5 (effect on fecal phosphorus excretion).
- n 5 ** p ⁇ 0.01 with significant difference compared to control group (t test)
- the medicament of the present invention containing a weakly basic anion exchange resin in which ferric ion is chelate-bonded can be used in the course of onset of hyperphosphatemia during renal failure and in administration after onset. It became clear that it could be effective.
- the medicament of the present invention has excellent adsorptivity and selectivity for phosphate ions, and efficiently adsorbs phosphate ions in a living body, and thus is useful for treating and preventing or preventing hyperphosphatemia. It is.
- the medicament of the present invention hardly adsorbs ions other than phosphate ions. As a result, it is possible to effectively treat and prevent or prevent hyperphosphatemia without losing the balance of metal ions essential for the living body.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/147,534 US6180094B1 (en) | 1996-07-19 | 1997-07-17 | Remedies for hyperphosphatemia |
EP97930826A EP0922461A4 (en) | 1996-07-19 | 1997-07-17 | MEDICINE AGAINST HYPERPHOSPHATANEMIA |
NO990225A NO990225L (no) | 1996-07-19 | 1999-01-18 | Medikamenter for behandling av hyperfosfatemi |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/207574 | 1996-07-19 | ||
JP20757496 | 1996-07-19 | ||
JP3146197 | 1997-01-31 | ||
JP9/31461 | 1997-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998003185A1 true WO1998003185A1 (fr) | 1998-01-29 |
Family
ID=26369934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/002486 WO1998003185A1 (fr) | 1996-07-19 | 1997-07-17 | Remedes contre l'hyperphosphatemie |
Country Status (7)
Country | Link |
---|---|
US (1) | US6180094B1 (ja) |
EP (1) | EP0922461A4 (ja) |
KR (1) | KR20000067929A (ja) |
CN (1) | CN1230118A (ja) |
CA (1) | CA2261750A1 (ja) |
NO (1) | NO990225L (ja) |
WO (1) | WO1998003185A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066607A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant |
WO2001066606A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci |
JP2009526086A (ja) * | 2006-03-24 | 2009-07-16 | リ,シビアオ | 燐酸過剰血による病気を治療する薬物及びその製造方法 |
WO2011125758A1 (ja) * | 2010-03-31 | 2011-10-13 | 富田製薬株式会社 | 透析組成物、血液透析システムおよび血液透析器 |
JP2012031210A (ja) * | 2004-03-30 | 2012-02-16 | Ilypsa Inc | イオン結合組成物 |
JP2014506673A (ja) * | 2011-02-11 | 2014-03-17 | コルゲート・パーモリブ・カンパニー | 歯垢を分析する方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2542968C (en) * | 2003-10-20 | 2013-06-04 | Framework Therapeutics, L.L.C. | Zeolite molecular sieves for the removal of toxins |
US7335795B2 (en) * | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
CA2551528A1 (en) * | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
EP1830832A1 (en) * | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
WO2007056405A2 (en) * | 2005-11-08 | 2007-05-18 | Genzyme Corporation | Magnesium-containing polymers for the treatment of hyperphosphatemia |
MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
JP2009542653A (ja) * | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | リン酸塩過剰血症のための鉄(ii)含有治療剤 |
ES2573636T3 (es) * | 2006-10-25 | 2016-06-09 | Wisconsin Alumni Research Foundation | Métodos para reducir la absorción de fosfato empleando un anticuerpo anti-Npt2B |
BRPI0716317A8 (pt) * | 2006-10-26 | 2019-02-05 | Aovatechnologies Inc | método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano |
CA2625522A1 (en) | 2007-04-20 | 2008-10-20 | Rohm And Haas Company | Method for removing phosphate from aqueous solutions |
AU2010276242B2 (en) | 2009-07-21 | 2014-05-29 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
AU2013278000A1 (en) * | 2012-06-21 | 2015-01-22 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of chronic kidney disease patients |
TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
CN104258829B (zh) * | 2014-09-24 | 2016-08-31 | 珠海健帆生物科技股份有限公司 | 血磷吸附剂及其制备方法、用于血液灌流的吸附柱 |
CN111773247B (zh) * | 2020-07-24 | 2022-04-05 | 荆门市第一人民医院 | 蔗糖铁在制备治疗高磷血症诱导的血管钙化药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005184A2 (en) * | 1993-08-11 | 1995-02-23 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3228231A1 (de) * | 1982-07-28 | 1984-02-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung |
CA2042870C (en) * | 1991-05-17 | 1996-11-26 | Leon Edward St. Pierre | Metal ion coordinated polyamine resins for the lowering of blood cholesterol |
US5487888A (en) | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
JPH072903A (ja) * | 1993-06-11 | 1995-01-06 | Tatsuaki Yamaguchi | アセチル化鉄キトサン錯体、その製法および用途 |
JPH09157283A (ja) * | 1995-12-13 | 1997-06-17 | Tatsuaki Yamaguchi | 燐酸吸着コロイド |
ES2162658T3 (es) * | 1996-03-05 | 2002-01-01 | Mitsubishi Chem Corp | Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia. |
-
1997
- 1997-07-17 CN CN97197937A patent/CN1230118A/zh active Pending
- 1997-07-17 EP EP97930826A patent/EP0922461A4/en not_active Withdrawn
- 1997-07-17 US US09/147,534 patent/US6180094B1/en not_active Expired - Fee Related
- 1997-07-17 CA CA002261750A patent/CA2261750A1/en not_active Abandoned
- 1997-07-17 WO PCT/JP1997/002486 patent/WO1998003185A1/ja not_active Application Discontinuation
- 1997-07-17 KR KR1019997000395A patent/KR20000067929A/ko not_active Application Discontinuation
-
1999
- 1999-01-18 NO NO990225A patent/NO990225L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005184A2 (en) * | 1993-08-11 | 1995-02-23 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
Non-Patent Citations (3)
Title |
---|
BIOINORG. CHEM., 1978, Vol. 9, No. 3, BROWN D.A. et al., "Design of Iron (III) Chelates in Oral Treatment of Anemia: Solution Properties and Absorption of Iron (III) Acetohydroxamate in Anemic Rats", pp. 255-275. * |
CLIN. SCI. MOL. MED., 1978, Vol. 54, No. 1, BURSAUX E. et al., "Oxygen Transport in Children on Maintenance Haemodialysis", pp. 85-91. * |
See also references of EP0922461A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066607A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant |
WO2001066606A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci |
US6844372B2 (en) | 2000-03-09 | 2005-01-18 | Hisamitsu Pharmaceutical Co., Inc. | Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
JP2012031210A (ja) * | 2004-03-30 | 2012-02-16 | Ilypsa Inc | イオン結合組成物 |
JP2009526086A (ja) * | 2006-03-24 | 2009-07-16 | リ,シビアオ | 燐酸過剰血による病気を治療する薬物及びその製造方法 |
WO2011125758A1 (ja) * | 2010-03-31 | 2011-10-13 | 富田製薬株式会社 | 透析組成物、血液透析システムおよび血液透析器 |
JPWO2011125758A1 (ja) * | 2010-03-31 | 2013-07-08 | 富田製薬株式会社 | 透析組成物、血液透析システムおよび血液透析器 |
JP2014506673A (ja) * | 2011-02-11 | 2014-03-17 | コルゲート・パーモリブ・カンパニー | 歯垢を分析する方法 |
US9310333B2 (en) | 2011-02-11 | 2016-04-12 | Colgate-Palmolive Company | Methods of analyzing plaque |
Also Published As
Publication number | Publication date |
---|---|
EP0922461A1 (en) | 1999-06-16 |
EP0922461A4 (en) | 2002-07-17 |
CA2261750A1 (en) | 1998-01-29 |
CN1230118A (zh) | 1999-09-29 |
US6180094B1 (en) | 2001-01-30 |
NO990225D0 (no) | 1999-01-18 |
NO990225L (no) | 1999-03-18 |
KR20000067929A (ko) | 2000-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998003185A1 (fr) | Remedes contre l'hyperphosphatemie | |
US4814354A (en) | Lipid regulating agents | |
US4822765A (en) | Process for treating activated carbon with aqueous ammonia | |
EP1381376B1 (en) | Water-absorbent polymers and their use | |
US4405596A (en) | Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level | |
US20020176840A1 (en) | Adsorbent for oral administration | |
JPS6211611B2 (ja) | ||
EP1809305A2 (en) | Phosphate binder with reduced pill burden | |
WO2004039381A1 (ja) | 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤 | |
JP6190044B2 (ja) | 高リン血症および鉄欠乏性貧血を治療する鉄型モンモリロナイト製剤とその調製方法 | |
WO2001076635A1 (fr) | Preparations destinees a la prevention de diarrhee liee aux acides biliaires | |
JPH05155776A (ja) | 高リン血症治療剤 | |
US6558667B2 (en) | Method for treating renal disease, and pharmaceutical composition for treating renal disease | |
CA2645574C (en) | A medicine used for curing hyperphosphatemia and its preparation method | |
JPS6136222A (ja) | 高リン酸血症治療剤 | |
JPS63152321A (ja) | 脂質調節組成物 | |
JPH11510499A (ja) | 腸管のリン酸塩結合のためのカルシウム含有組成物およびその製造法 | |
CN107397810B (zh) | 基于铁的氢氧化物-桃胶的磷结合剂、其制备方法及其应用 | |
JP2884124B2 (ja) | リン吸着剤 | |
JP2001048791A (ja) | 高リン血症予防および/または治療剤 | |
JPH08198760A (ja) | 経口用リン酸イオン吸着剤 | |
JPH08208489A (ja) | 腎不全治療剤 | |
EP1407772B1 (en) | Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases | |
RU2777203C1 (ru) | Способ выведения из организма солей тяжелых металлов | |
JPH072903A (ja) | アセチル化鉄キトサン錯体、その製法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97197937.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09147534 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2261750 Country of ref document: CA Ref document number: 2261750 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997000395 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997930826 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997930826 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997000395 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997000395 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997930826 Country of ref document: EP |